tirzepatide surmount-1 nejm 2022 weight loss percent (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT-1 Tirzepatide Trial — 22.5%

Speed comes with repetition

If youre ready to gain control of your health, reduce cravings, and move toward a healthier weight, this could be the solution that aligns with your goals

How much weight you can expect to lose at each dose level Clinical trial data provides realistic expectations for what each dose level typically achieves

For researchers who prioritize cardiovascular safety data, tirzepatide currently offers more reassurance simply because the data exists

We emphasize that medications create a foundation for success, but long-term transformation often combines medical treatment with surgical refinement to achieve balance and proportion